Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04264858
Other study ID # WuhanUH-2019 nCoV-Ig
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 17, 2020
Est. completion date May 31, 2020

Study information

Verified date March 2020
Source Wuhan Union Hospital, China
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The new coronavirus pneumonia is an acute infectious pneumonia. The pathogen is a previously unknown new coronavirus, namely 2019 new coronavirus (2019 novel coronavirus, 2019 nCoV). However, there is no specific anti-viral drug. It has been found that the specific antibodies against virus antigen are produced after these patients were cured, which could block the infection of 2019 nCoV on the host cells. At present, immunoadsorption is the most direct, rapid and effective method to separate immunoglobulin from the cured patients. Therefore, the study aims to prepare the immunoglobulin from 2019-ncov pneumonia cured patients, evaluate the efficacy and safety of the immunoglobulin in 2019-ncov pneumonia cured patients on the treatment of acute severe 2019-ncov pneumonia, and provide a new strategy for the treatment of 2019-ncov pneumonia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date May 31, 2020
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Volunteers who have understood and signed the informed consent;

2. Age =18 years, gender unlimited;

3. Patients diagnosed with acute severe 2019-nCoV pneumonia:

1. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.

2. Lung involvement confirmed with pulmonary CT scan.

3. At least one of the following conditions should be met: respiratory distress, RR = 30 times/min; oxygen saturation = 93% in resting state; PaO2/FiO2 = 300mmHg; respiratory failure and mechanical ventilation are required; shock occurs; ICU monitoring and treatment is required in combination with other organ failure.

Exclusion Criteria:

1. Viral pneumonia with other viruses besides 2019-nCoV.

2. Patients are not suitable for immunoglobulin therapy.

3. Participation in other studies.

4. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Immunoglobulin of cured patients
0.2g/kg, ivdrip, once a day, for 3 days
?-Globulin
0.2g/kg, ivdrip, once a day, for 3 days

Locations

Country Name City State
China Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Clinical Improvement (TTCI) TTCI is defined as the time (in days) from initiation of study treatment (active or placebo) until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death).
Six-category ordinal scale: 6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy; 3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC); 2. Hospitalization, not requiring supplemental oxygen; 1. Hospital discharge.
Abbreviation: IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; HFNC, High-flow nasal cannula.
up to 28 days
Secondary Clinical status assessed by the ordinal scale on days 7, 14, 21, and 28 up to 28 days
Secondary The differences in oxygen intake methods 1. No need for supplemental oxygenation; 2. nasal cathete oxygen inhalation;3. Mask oxygen inhalation;4. Noninvasive ventilator oxygen supply;5. Invasive ventilator oxygen supply. up to 28 days
Secondary Duration (days) of supplemental oxygenation up to 28 days
Secondary Duration (days) of mechanical ventilation up to 28 days
Secondary The mean PaO2/FiO2 up to 28 days
Secondary The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days] The detection frequency could be increased according to clinician's decision up to 28 days
Secondary Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days] up to 28 days
Secondary Dynamic changes of 2019-nCoV antibody titer in blood The antibody titer is detected on days 3 and 28 up to 28 days
Secondary Length of hospital stay (days) up to 28 days
Secondary All cause mortality up to 28 days
See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Withdrawn NCT04272710 - Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Completed NCT04260594 - Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus Phase 4
Active, not recruiting NCT04273763 - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) N/A
Not yet recruiting NCT04270383 - Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
Terminated NCT04261907 - Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection N/A
Not yet recruiting NCT04261426 - The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia Phase 2/Phase 3
Recruiting NCT04254874 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia Phase 4
Recruiting NCT04255017 - A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Phase 4
Not yet recruiting NCT04356508 - COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Phase 2
Terminated NCT04321928 - Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary N/A